Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PAM | P19021 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27849267 | 1.00 | IDO1 (0.53) | IDO1PPARGNFE2L2LMNAPAM | |
| SCHEMBL11355618 | 0.85 | IDO1 (0.57) | IDO1PPARGNFE2L2LMNAPAM | |
| SCHEMBL11285547 | 0.85 | IDO1 (0.57) | IDO1PPARGNFE2L2LMNAPAM | |
| SCHEMBL16550586 | 0.82 | NFE2L2 (0.45) | PPARGNFE2L2 | |
| SCHEMBL6042289 | 0.82 | SIGMAR1 (0.42) | IDO1PPARGNFE2L2LMNAPAM | |
| SCHEMBL6042296 | 0.82 | SIGMAR1 (0.42) | IDO1PPARGNFE2L2LMNAPAM | |
| SCHEMBL16550588 | 0.82 | NFE2L2 (0.45) | PPARGNFE2L2 | |
| SCHEMBL14602799 | 0.82 | PTGS1 (0.45) | IDO1PPARGLMNAMMP1MMP2 | |
| SCHEMBL778798 | 0.81 | IDO1 (0.53) | IDO1PPARGNFE2L2LMNAPAM | |
| SCHEMBL14955146 | 0.81 | IDO1 (0.53) | IDO1PPARGNFE2L2LMNAPAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215050-B1 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | NEUROTECH PHARMACEUTICALS CO LTD (KR) | 2012-06-27 | — | — | EP | claimed |
| US-20110028757-A1 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2011-02-03 | — | — | US | claimed |
| EP-2215050-A2 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | Neurotech Pharmaceuticals Co., Ltd. (KR) | 2010-08-11 | — | — | EP | claimed |
| WO-2009064084-A2 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | NEUROTECH CO., LTD. (KR) | 2009-05-22 | — | — | WO | claimed |
| CN-106083757-B | 2- pi-allyl -1- oxygen -2,3- dihydro -1,2- benzisothiazoles and its preparation method and application | 四川墨凯科技有限公司 | 2018-05-25 | — | — | CN | disclosed |
| CN-106083757-A | 2 pi-allyl 1 oxygen 2,3 dihydro 1,2 benzisothiazoles | 四川墨凯科技有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-103787936-B | A kind of industrialized production is with the trans simple synthesis to first sulfydryl cinnamyl alcohol | 新发药业有限公司 | 2016-06-08 | — | — | CN | disclosed |
| EP-2215050-B1 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | NEUROTECH PHARMACEUTICALS CO LTD (KR) | 2012-06-27 | — | — | EP | disclosed |
| US-20110028757-A1 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2011-02-03 | — | — | US | disclosed |
| CN-101921249-A | Synthesizing method of (2S,3S)-3-(4- methylsulphonyl phenyl)-2,3-glycide | UNIV FUDAN | 2010-12-22 | — | — | CN | disclosed |
| EP-2215050-A2 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | Neurotech Pharmaceuticals Co., Ltd. (KR) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009064084-A2 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | NEUROTECH CO., LTD. (KR) | 2009-05-22 | — | — | WO | disclosed |
| EP-0276920-B1 | (2-CYANO-2-(PHENYL OR NAPHTHYL)-2-SUBSTITUTED-ETHYL) PYRAZINES, PYRIMIDINES AND PYRIDAZINES | ROHM AND HAAS COMPANY (US) | 1991-04-03 | — | — | EP | disclosed |
| EP-0276920-A1 | (2-Cyano-2-(phenyl or naphthyl)-2-substituted-ethyl) pyrazines, pyrimidines and pyridazines | ROHM AND HAAS COMPANY (US) | 1988-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028757-A1 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | PAH, HACL2, HAAO | IDO1 3909/4885PPARG 1401/4885NFE2L2 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.